The new patent application was filed for novel dosing combinations of RVX-208 and leading statin therapeutics based on the analysis of the Phase II study data.
The study data revealed that certain doses of RVX-208, in combination with leading statin drugs, markedly improved ApoA-I production, HDL and large HDL particles, including important aspects of LDL and ApoB particles.
These improvements were seen in patients who were on best standard of care currently available.
Resverlogix Medical Affairs senior vice president Jan Johansson said that the bonus finding of ApoB and LDL lowering while on statins and not in placebo’s was a surprise finding and is useful in selecting the best statin co-medications going forward for maximum treatment effect.
"The effects seem most efficacious in the leading stains, being Pfizer‘s Lipitor and AstraZeneca‘s Crestor," Johansson said.